Assertio Holdings Inc is a drug manufacturers-specialty & generic business based in the US. Assertio shares (ASRT) are listed on the NASDAQ and all prices are listed in US Dollars. Assertio employs 27 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $2.19 |
|---|---|
| 52-week range | $0.85 - $5.80 |
| 50-day moving average | $1.80 |
| 200-day moving average | $1.52 |
| Wall St. target price | $4.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.78 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.19 from 2022-01-24
| 1 week (2022-01-18) | 2.34% |
|---|---|
| 1 month (2021-12-23) | -0.45% |
| 3 months (2021-10-25) | 119.00% |
| 6 months (2021-07-23) | 75.20% |
| 1 year (2021-01-25) | 217.35% |
|---|---|
| 2 years (2020-01-24) | 95.54% |
| 3 years (2019-01-25) | 4.18 |
| 5 years (2017-01-25) | 18.09 |
Valuing Assertio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Assertio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Assertio's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $34.1 million.
The EBITDA is a measure of a Assertio's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $109.7 million |
|---|---|
| Operating margin TTM | 4.92% |
| Gross profit TTM | $92.3 million |
| Return on assets TTM | 1.07% |
| Return on equity TTM | -35% |
| Profit margin | -27.56% |
| Book value | $2.17 |
| Market capitalisation | $104 million |
TTM: trailing 12 months
We're not expecting Assertio to pay a dividend over the next 12 months.
Assertio's shares were split on a 1:4 basis on 17 May 2021. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Assertio shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Assertio shares which in turn could have impacted Assertio's share price.
Over the last 12 months, Assertio's shares have ranged in value from as little as $0.85 up to $5.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Assertio's is 1.664. This would suggest that Assertio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Assertio Holdings, Inc. , a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company's pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, an NSAID for relief of mild to moderate acute pain; and SPRIX, an NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.